Humana has delivered a sharp year to date rebound, and that kind of move naturally raises a question about what investors are really paying for in terms of earnings power. With the stock now trading around US$410, the issue is whether the current price lines up with what the healthcare insurer is actually generating per share.
- The share price is up 55.2% year to date, which places significant focus on whether the current earnings profile can support this stronger level.
- The business relies heavily on converting premium income into consistent profit margins, so any shift in medical cost trends or pricing discipline can materially change how supportive its earnings are for today's valuation.
- Your read on Humana is one view; the desks covering it have another. See what analysts think Humana's shares could be worth.
The issue now is whether Humana's current earnings justify the valuation that this year to date rally has created.
If you are weighing whether Humana's 55.2% year to date rebound is well supported by its earnings profile, it can help to compare it with 34 high quality undervalued stocks.
Is Humana a Bargain on Earnings?
The P/E ratio fits Humana because earnings are a central yardstick for a mature insurer that lives and dies by underwriting discipline. At roughly 38.5x, Humana's P/E sits well above the Healthcare industry average of about 25.0x and the peer group near 24.7x, so the market is attaching a richer tag to each dollar of current profit than it does for many similar businesses.
The internal fair multiple implied by the model, which factors in Humana's margins, growth assumptions, size, and sector risks, points to a higher P/E than today. That places the current 38.5x below what this framework would expect and indicates the stock screens as undervalued on earnings against that tailored benchmark. For you as a holder or potential buyer, the key question is whether Humana's earnings profile and risk mix justify closing that gap or keeping the current discount in place. Explore the numbers behind Humana's P/E valuation.
The Humana Narrative: What Would Justify Today's Price?
Humana Narratives pick up where the P/E puzzle leaves off by spelling out which combinations of future growth, margins, and earnings power would need to hold for the stock to look meaningfully cheaper or more expensive than today. Each scenario treats fair value as a thesis about how Humana's business might develop that you can revisit over time. They sit alongside other discussion on Simply Wall St's Community page.
Humana holders in the community are split between those who see a tightening margin story paying off and those focused on rising regulatory heat.
Bull case: 12% undervalued
"Humana’s multiyear Medicare Advantage margin restoration plan that targets at least a 3% pretax margin by 2028, including 2027 bid discipline and exits from about 600,000 lower return plans..."
Discover why this Narrative puts Humana at 12% undervalued.
Bear case: 93% overvalued
"Across the industry, regulators are sharpening their focus on how health plans document risk adjustment data and apply prior authorization standards..."
Explore why this Narrative puts Humana at 93% overvalued.
Before moving on from Humana, there is one more piece to check
Price and earnings only tell part of the story. The people charting Humana's direction and the way their rewards are structured can strongly influence how that story plays out. See who runs Humana and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com